These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7076990)

  • 1. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy.
    Golden DB; Meyers DA; Kagey-Sobotka A; Valentine MD; Lichtenstein LM
    J Allergy Clin Immunol; 1982 Jun; 69(6):489-93. PubMed ID: 7076990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.
    Müller U; Helbling A; Berchtold E
    J Allergy Clin Immunol; 1992 Feb; 89(2):529-35. PubMed ID: 1740583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy.
    Golden DB; Lawrence ID; Hamilton RH; Kagey-Sobotka A; Valentine MD; Lichtenstein LM
    J Allergy Clin Immunol; 1992 Sep; 90(3 Pt 1):386-93. PubMed ID: 1527321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose dependence of Hymenoptera venom immunotherapy.
    Golden DB; Kagey-Sobotka A; Valentine MD; Lichtenstein LM
    J Allergy Clin Immunol; 1981 May; 67(5):370-4. PubMed ID: 7229226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
    Ruëff F; Wenderoth A; Przybilla B
    J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and immunologic follow-up of patients who stop venom immunotherapy.
    Keating MU; Kagey-Sobotka A; Hamilton RG; Yunginger JW
    J Allergy Clin Immunol; 1991 Sep; 88(3 Pt 1):339-48. PubMed ID: 1890261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of an in-hospital insect sting challenge as a criterion for application or omission of venom immunotherapy.
    Blaauw PJ; Smithuis OL; Elbers AR
    J Allergy Clin Immunol; 1996 Jul; 98(1):39-47. PubMed ID: 8765816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sting challenge test in Hymenoptera venom allergy: pros and cons.
    Bilò MB; Brianzoni MF; Garritani MS; Antonicelli L; Farabollini B; Bonifazi F
    Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):377-81. PubMed ID: 14768522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients.
    Fricker M; Helbling A; Schwartz L; Müller U
    J Allergy Clin Immunol; 1997 Jul; 100(1):11-5. PubMed ID: 9257781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled trial of immunotherapy in insect hypersensitivity.
    Hunt KJ; Valentine MD; Sobotka AK; Benton AW; Amodio FJ; Lichtenstein LM
    N Engl J Med; 1978 Jul; 299(4):157-61. PubMed ID: 78446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme-like immunosorbent assay (ELISA) for immunoglobulin G antibodies against insect venoms.
    Grant JA; Goldblum RM; Rahr R; Thueson DO; Farnam J; Gillaspy J
    J Allergy Clin Immunol; 1981 Aug; 68(2):112-8. PubMed ID: 6166648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse reactions to venom immunotherapy.
    Ramirez DA; Londono S; Evans R
    Ann Allergy; 1981 Dec; 47(6):435-9. PubMed ID: 7325415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgG and IgE antibodies after immunotherapy with bee and wasp venom.
    Kemeny DM; Lessof MH; Patel S; Youlten LJ; Williams A; Lambourn E
    Int Arch Allergy Appl Immunol; 1989; 88(1-2):247-9. PubMed ID: 2707888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge.
    van Halteren HK; van der Linden PW; Burgers JA; Bartelink AK
    J Allergy Clin Immunol; 1997 Dec; 100(6 Pt 1):767-70. PubMed ID: 9438484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.
    von Moos S; Graf N; Johansen P; Müllner G; Kündig TM; Senti G
    Int Arch Allergy Immunol; 2013; 160(1):86-92. PubMed ID: 22948338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of prolonged venom immunotherapy in children.
    Graft DF; Schuberth KC; Kagey-Sobotka A; Kwiterovich KA; Niv Y; Lichtenstein LM; Valentine MD
    J Allergy Clin Immunol; 1987 Aug; 80(2):162-9. PubMed ID: 3611537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunotherapy against hymenoptera venom: report of ten patients].
    Guzmán M MA; Salinas L J; Toche P P; Marinovic M MA; Gallardo O AM
    Rev Med Chil; 2007 Dec; 135(12):1566-71. PubMed ID: 18357358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the allergenicity and antigenicity of yellow jacket and hornet venoms.
    Reisman RE; Mueller U; Wypych J; Elliott W; Arbesman CE
    J Allergy Clin Immunol; 1982 Mar; 69(3):268-74. PubMed ID: 6801104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report of venom immunotherapy for a patient with large local reactions.
    Hamilton RG; Golden DB; Kagey-Sobotka A; Lichtenstein LM
    Ann Allergy Asthma Immunol; 2001 Aug; 87(2):134-7. PubMed ID: 11527245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.